Ikena Oncology, Inc. (IKNA): Price and Financial Metrics
IKNA Price/Volume Stats
| Current price | $1.26 | 52-week high | $7.64 |
| Prev. close | $1.24 | 52-week low | $1.02 |
| Day low | $1.22 | Volume | 184,600 |
| Day high | $1.29 | Avg. volume | 376,609 |
| 50-day MA | $1.41 | Dividend yield | N/A |
| 200-day MA | $2.96 | Market Cap | 60.81M |
IKNA Stock Price Chart Interactive Chart >
Ikena Oncology, Inc. (IKNA) Company Bio
Ikena Oncology, Inc., a targeted oncology company, focuses on developing novel cancer therapies targeting key signaling pathways that drive the formation and spread of cancer. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway. It is also developing a small molecule inhibitor program against ERK5 in the RAS signaling pathway; IK-175, a selective AHR antagonist; IK-412, a recombinant human kynurenine-degrading enzyme; and IK-007, an oral selective EP4 receptor antagonist for the treatment of microsatellite stable colorectal cancer. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts.
Latest IKNA News From Around the Web
Below are the latest news stories about IKENA ONCOLOGY INC that investors may wish to consider to help them evaluate IKNA as an investment opportunity.
Broker Revenue Forecasts For Ikena Oncology, Inc. (NASDAQ:IKNA) Are Surging HigherIkena Oncology, Inc. ( NASDAQ:IKNA ) shareholders will have a reason to smile today, with the analysts making... |
Ikena Oncology Shares Initial Positive and Differentiated Dose Escalation Data from IK-930 Phase I Trial and Reports Third Quarter 2023 Financial ResultsFavorable safety profile in dose escalation shown to date; selective TEAD1 inhibition with IK-930 resulted in minimal treatment-related proteinuria without any dose reductions or treatment interruptions Encouraging signs of clinical activity and tumor shrinkage in multiple patients with difficult-to-treat epithelioid hemangioendothelioma (EHE) during dose escalation Additional IK-930 clinical data update planned for the second half of 2024; increased focus on enrollment of targeted populations i |
Ikena Oncology to Present at Multiple November 2023 Investor ConferencesBOSTON, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that management will participate in three upcoming investor conferences in November. Details are as follows: Stifel Healthcare Conference, November 14-15, 2023One-on-One Investor Meetings November 14, 2023Presentation: November 14, 2023 at 1:50pm EST Jefferies London Healthcare Conference, Novemb |
Pliant Therapeutics, Inc. (PLRX) Soars 14.3%: Is Further Upside Left in the Stock?Pliant Therapeutics, Inc. (PLRX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road. |
Ikena Oncology to Participate in September 2023 Investor ConferencesBOSTON, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that management will participate in two upcoming investor conferences in New York, NY. Details are as follows: Morgan Stanley 21st Annual Global Healthcare Conference, September 11-13, 2023One-on-One Investor Meetings September 11, 2023Fireside Chat: Monday, September 11, 2023, at 3:35pm ETWebca |
IKNA Price Returns
| 1-mo | -18.97% |
| 3-mo | -17.11% |
| 6-mo | -62.72% |
| 1-year | -73.31% |
| 3-year | -93.15% |
| 5-year | N/A |
| YTD | -36.04% |
| 2023 | -25.94% |
| 2022 | -78.79% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...